Juniper Pharmaceuticals Inc (JNP.OQ)
JNP.OQ on NASDAQ Stock Exchange Global Select Market
8.65USD
23 Apr 2018
8.65USD
23 Apr 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$8.65
$8.65
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
18,510
18,510
52-wk High
$13.10
$13.10
52-wk Low
$3.90
$3.90
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 11.79 | 2.136 |
| Sep '17 | 12.99 | -0.130 | |
| Jun '17 | 13.96 | 0.007 | |
| Mar '17 | 11.25 | -0.134 | |
| FY 2016 | Dec '16 | 20.93 | 0.858 |
| Sep '16 | 11.56 | 0.022 | |
| Jun '16 | 11.61 | -0.211 | |
| Mar '16 | 10.48 | -0.153 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 1 | 19.16 | 19.16 | 19.16 | -- |
| Quarter Ending Sep-18 | 1 | 23.95 | 23.95 | 23.95 | -- |
| Year Ending Dec-18 | 1 | 118.37 | 118.37 | 118.37 | 50.74 |
| Year Ending Dec-19 | 1 | 104.25 | 104.25 | 104.25 | 60.43 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 1 | 0.13 | 0.13 | 0.13 | -- |
| Quarter Ending Sep-18 | 1 | 0.25 | 0.25 | 0.25 | -- |
| Year Ending Dec-18 | 1 | 3.50 | 3.50 | 3.50 | -0.34 |
| Year Ending Dec-19 | 1 | 1.32 | 1.32 | 1.32 | 0.55 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 6.24 | 30.95 | 32.74 | |
| P/E High - Last 5 Yrs. | 13.32 | 40.70 | 45.72 | |
| P/E Low - Last 5 Yrs. | 5.69 | 23.63 | 24.22 | |
| Beta | 0.04 | 0.89 | 0.88 | |
| Price to Sales (TTM) | 0.88 | 3.94 | 5.71 | |
| Price to Book (MRQ) | 1.26 | 4.80 | 5.37 | |
| Price to Tangible Book (MRQ) | 1.66 | 5.61 | 6.95 | |
| Price to Cash Flow (TTM) | 5.04 | 22.91 | 23.32 | |
| % Owned Institutions | 39.36 | 1.21 | 2.17 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.56 | 1.50 | |
| Dividend Yield - 5 Year Avg | -- | 1.57 | 1.51 | |
| Dividend 5 Year Growth Rate | -- | 4.47 | 5.32 | |
| Payout Ratio(TTM) | 0.00 | 45.35 | 43.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 20.21 | 3.69 | 9.21 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 38.33 | 4.83 | 5.69 | |
| Sales - 5 Yr. Growth Rate | 4.85 | 10.08 | 10.32 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 103.29 | 16.36 | 19.36 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 278.54 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -20.63 | 9.87 | 10.76 | |
| Capital Spending - 5 Yr. Growth Rate | 22.22 | 15.52 | 15.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 1.85 | 2.12 | 2.19 |
| Current Ratio (MRQ) | 2.17 | 2.90 | 2.98 |
| LT Debt to Equity (MRQ) | 8.43 | 9.88 | 12.18 |
| Total Debt to Equity (MRQ) | 9.71 | 13.86 | 16.45 |
| Interest Coverage (TTM) | -47.59 | 35.89 | 32.81 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 55.48 | 54.81 | 54.44 | |
| Gross Margin - 5 Yr. Avg. | 50.67 | 52.15 | 52.20 | |
| EBITD Margin (TTM) | 16.61 | -- | -- | |
| EBITD - 5 Yr. Avg | 14.79 | 18.57 | 10.96 | |
| Operating Margin (TTM) | 12.97 | 14.36 | 4.73 | |
| Operating Margin - 5 Yr. Avg. | 9.29 | 14.52 | 6.40 | |
| Pre-Tax Margin (TTM) | 14.01 | 14.82 | 5.57 | |
| Pre-Tax Margin - 5 Yr. Avg. | 14.62 | 14.90 | 6.81 | |
| Net Profit Margin (TTM) | 13.95 | 11.08 | 1.87 | |
| Net Profit Margin - 5 Yr. Avg. | 14.19 | 11.20 | 3.09 | |
| Effective Tax Rate (TTM) | 0.48 | 23.16 | 23.04 | |
| Effective Tax Rate - 5 Yr. Avg. | 2.91 | 23.42 | 23.96 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 415,029 | 938,079,949 | 846,830,978 | |
| Net Income/Employee (TTM) | 57,878 | 110,368,367 | 99,616,195 | |
| Receivable Turnover (TTM) | 8.84 | 5.63 | 5.78 | |
| Inventory Turnover (TTM) | 5.61 | 2.59 | 3.35 | |
| Asset Turnover (TTM) | 1.07 | 0.95 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 14.93 | 11.40 | 10.95 | |
| Return on Assets - 5 Yr. Avg. | 10.44 | 12.91 | 12.31 | |
| Return on Investment (TTM) | 20.65 | 14.84 | 14.38 | |
| Return on Investment - 5 Yr. Avg. | 12.26 | 16.88 | 16.10 | |
| Return on Equity (TTM) | 23.82 | 16.34 | 16.07 | |
| Return on Equity - 5 Yr. Avg. | 13.77 | 17.98 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 42.54 | 23.14 | 4.85 |
| EPS (TTM) % | 484.48 | -2.80 | -20.63 |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Juniper Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 6.82 | 3.14 | 72 | 23 |
| 13 Week | -6.93 | -11.46 | 34 | 34 |
| 26 Week | 11.90 | 3.40 | 74 | 29 |
| 52 Week | -16.07 | -28.86 | 31 | 12 |
| YTD | -16.07 | -26.29 | 24 | 25 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Juniper Pharmaceuticals Appoints Richard Messina To Board Of Directors
- BRIEF-Juniper Pharmaceuticals Qtrly Basic EPS $0.11
- BRIEF-Juniper Pharmaceuticals To Explore Strategic Alternatives
- BRIEF-Juniper Pharmaceuticals Announces Extension Of Supply Agreement For Crinone
- German stocks - Factors to watch on January 3
Institutional Holders
| % Shares Owned: | 40.95% |
| # of Holders: | 51 |
| Total Shares Held: | 4,493,809 |
| 3 Mo. Net Change: | -29,994 |
| # New Positions: | 3 |
| # Closed Positions: | 1 |
| # Increased Positions: | 4 |
| # Reduced Positions: | 3 |
| # Net Buyers: | 1 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.